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Abstract 
Introduction: One of pathogenetic links of development of endothelial dysfunction, as an 
early marker of cardiovascular disease and comorbidity, is a low-grade systemic 
inflammation. In this regard, correction of cytokines imbalance is one of the possible ways 
of prevention and treatment of major chronic noninfectious diseases. 
Aims: To study the endothelium protective effects of anti–IL-6 receptor monoclonal 
antibodies tocilizumab in experimental preclinical studies in a model of endothelial 
dysfunction associated with the low-grade systemic inflammation. 
Methods: The study was performed with 40 white male Wistar rats. The endothelial 
dysfunction associated with the low-grade systemic inflammation and oxidative stress was 
produced by sequential administration of gentamicin, bacterial lipopolysaccharide and N-nitro-
L-arginine methyl ester. The administration of tocilizumab (Actemra®, F. Hoffmann-La Roche 
Ltd, Switzerland) was performed at 6 day from the experiment start in doses of 4 mg/kg and 8 
mg/kg once. The endothelium protective activity was studied at 34th day from the s the 
experiment start through the analysis of changes of pharmacological vascular tests and 
calculation of the endothelial dysfunction coefficient. The cytokine profile was assessed by 
measuring of serum concentrations of tumor necrosis factor-α, interleukin-6 and interleukin-
10 by enzyme linked immunosorbent assay. 
Results: In the model of endothelial dysfunction associated with the low-grade systemic 
inflammation and oxidative stress, tocilizumab at the doses of 4 mg/kg and 8 mg/kg had 
the dose-dependent endothelium protective action that is logged to reduce of the endothelial 
dysfunction coefficient from 7.2±0.6 to 2.8±0.3 and 2.3±0.2, respectively. In addition, 
there was normalization of the cytokine profile in the form of lower serum concentrations 
of the tumor necrosis factor-α, interleukin-6 and interleukin-10. 
Conclusion: Tocilizumab (at the doses of 4 mg/kg and 8 mg/kg) after one dose delivery 
has a pronounced endothelium protective activity in the model of endothelial dysfunction 
associated with the low-grade systemic inflammation and oxidative stress and prevents of 
the cytokine profile imbalance. 
Key words: endothelial dysfunction, low-grade systemic inflammation, interleukin-6, 
tocilizumab. 
 
Introduction 
Endothelial dysfunction is an early marker 
and predictor of cardiovascular diseases [1, 2, 3, 
4, 5]. It is characterized by dysfunctionof 
relaxation caused by nitric oxide (NO) and other 
vasodilatory compounds (such as prostacyclin), 
whereas the production of endothelial 
vasoconstrictor factors increases [6, 7, 8]. Pro-
oxidant and proinflammatory vascular 
environment is another endothelial dysfunction 
characteristic [8, 9].  
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Low-grade chronic inflammation has a close 
pathogenetic connection with the development of 
endothelial dysfunction. Key molecules that 
trigger the main pathogenetic links are  
C-reactive protein and proinflammatory 
cytokines such as tumor necrosis factor alpha, 
interleukins 1β and 6 [1, 6, 10, 11]. The increase 
of their concentration in the serum may lead to 
reduction of NO production by endothelial nitric 
oxide synthase (eNOS) inhibiting [6, 12, 13], and 
the increasing of adhesion molecules expression, 
stimulating the migration of white blood cells and 
initiate the proliferation of smooth muscle cells of 
blood vessels [14, 15]. 
In this regard, the search and preclinical 
studies of drugs with endothelium protective 
properties aimed at correcting of the cytokines 
imbalance are one of the most promising areas of 
targeted therapy. 
Materials and methods 
Animals 
The study was performed with 40 white male 
Wistar rats weighing 220±10 g. Animals were 
kept under controlled environmental conditions 
when the air temperature is +18-25° C, humidity 
is 40-60%, under a 12-hour lighting cycle. Plan 
and research protocol were approved by the local 
ethics committee (protocol №12-2016 from 
21.11.2016). Studies were conducted in 
compliance with ethical norms and rules with 
regard to the requirements of the European 
Convention for the protection of vertebrate 
animals using for experimental and other 
scientific purposes (1986), principles of good 
laboratory practice, state standard 33044-2014 
and the order of the Ministry of health of the 
Russian Federation No. 199n «On approval of 
Rules of good laboratory practice». 
Experimental groups 
All animals were divided into 4 groups of 10 
animals each (table 1). 
Table 1 
The experimental groups of animals (n=10) 
 
Group Description 
A Intact animals 
B A control group with the modeling of endothelial dysfunction associated with the low-grade 
systemic inflammation and oxidative stress 
C A group with tocilizumab (Actemra®, F. Hoffmann-La Roche Ltd, Switzerland) administration 
at the dose of 4 mg/kg on the background of endothelial dysfunction  
D A group with tocilizumab (Actemra®, F. Hoffmann-La Roche Ltd, Switzerland) administration 
at the dose of 8 mg/kg on the background of endothelial dysfunction 
 
The endothelial dysfunction associated with 
the low-grade systemic inflammation and 
oxidative stress was modulated by the following 
way: gentamicin at a dose of 20 mg/kg was 
administered intraperitoneally once a day, for 5 
days. After administration of gentamicin, there 
was started the administration of the E. coli 
lipopolysaccharide type О55:B5 at a dose of 1 
mg/kg intraperitoneally once every week for three 
weeks. At the 27th day from the experiment start 
the animals of the experimental group were 
intraperitoneally injected with N-nitro-L-arginine 
methyl ester (L-NAME) at a dose of 25 mg/kg 
daily for week.  
The administration of tocilizumab was 
performed intraperitoneally once at 6 day after the 
experiment start in doses of 4 and 8 mg/kg, 
respectively. 
Evaluation of hemodynamic and 
pharmacological vascular tests 
At the 34th day from the experiment start 
under anesthesia (chloral hydrate 300 mg/kg) 
there was catheterized the left carotid artery for 
registration of hemodynamic parameters: systolic, 
mean and diastolic arterial pressure (SBP, MAP 
and DBP), measuring by the sensor TSD104A and 
hardware and software MP150 complex produced 
by «Biopac System inc.», the USA. There were 
conducted functional tests: endothelium-
dependent vasodilatation (EDVD) after 
intravenous administration of acetylcholine (AC) 
at a dose of 40 mcg/kg and endothelium-
independent vasodilatation (EIVD) after 
intravenous administration of nitroprusside 
sodium (NP) at a dose of 30 mg/kg.  
To evaluate the severity of endothelial 
dysfunction there was used the endothelial 
dysfunction coefficient (EDC), calculated as the 
ratio of the areas of the triangles above the curve 
recovery of blood pressure after nitroprusside and 
acetylcholine administration. 
The evaluation of cytokine profile 
Blood samples from each rat was centrifuged 
at 3000 rpm for 15 minutes, the plasma was 
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placed in a plastic test tube type "Eppendorf" and 
frozen at -20°C until analyzed. Serum 
concentrations of TNF-α, IL-6 and IL-10 were 
determined by the enzyme linked immunosorbent 
assay. The results were expressed in pg/ml. 
Statistical data processing 
Statistical analysis of obtained data was 
performed in Microsoft Excel. "Descriptive 
statistics" was used to calculate the mean value (M) 
and standard error of the mean (m). "The two-
sample t test with unequal variances" was used to 
compare the data of different groups of animals and 
determining the significance of differences between 
them. Statistically significant differences were 
considered when p<0.05. 
Results 
The results of the assessment of hemodynamic 
and vascular pharmacological tests 
Modeling of the endothelial dysfunction 
associated with the low-grade systemic 
inflammation and oxidative stress, caused arterial 
hypertension (SBP – 173.0±15.2, DBP – 
134.0±3.9, MAP – 152.0±11.2 mm Hg) and led to 
a greater loss of the arterial blood pressure after 
the acetylcholine administration (SBP to 
102.9±8.1, DBP to 66.9±8.0, MAP to  
79.2±4.8 mm Hg) and less loss of it after the 
nitroprusside administration (SBP to 92.8±4.7, 
DBP to 47.1±4.2 and MAP to 62.0±2.9 mm Hg) 
in comparison with the intact animals. 
Tocilizumab administration dose-
dependently reduced the severity of hypertension, 
however, did not allow to achieve the values of 
the intact animals group (table 2). On the other 
hand, processing of the experimental data allowed 
to establish that tocilizumab has the strong 
endothelium protective action, expressed in a 
statistically significant decrease of the endothelial 
dysfunction coefficient to 2.8±0.3 and 2.3±0.2 in 
the animal groups receiving the drug at the doses 
of 4 and 8 mg/kg, respectively (table 3). 
Table 2 
Dynamics of hemodynamic parameters in the experimental animal groups (M ± m; n = 10) 
 
Group of animals SBP, mm Hg DBP, mm Hg MAP, mm Hg 
A (raw values) 137±3.7 101.9±4.3 115.0±1.9 
EDVD 84.3±4.4. 38.7±2.8 53.9±2.7 
EIVD 83.0±3.7 42.1±4.4 55.7±3.5 
B (raw values) 190.3±6.7* 145.0±3.9* 160.1±4.6* 
EDVD 110.6±5.2* 82.8±6.6* 92.1±6.1* 
EIVD 88.7±4.7* 50.8±4.2* 63.4±4.1* 
C (raw values) 157.9±6.9** 133.0±4.1** 141.6±4.4 
EDVD 86.1±3.8** 47.2±3.6** 59.0±3.2 
EIVD 94.6±3.1** 43.9±0.9** 60.8±1.2 
D (raw values) 153.9±4.5** 128.0±1.7** 138.2±2.0 
EDVD 79.9±2.6** 56.4±2.1** 64.2±1.9 
EIVD 105.5±3.7** 45.9±2.1** 65.8±1.8 
Comment: SBP – systolic blood pressure; DBP – diastolic blood pressure; MAP – mean arterial pressure; EDVD – 
endothelium-dependent vasodilatation; EIVD – endothelium-independent vasodilatation; * – р<0.05 in comparison 
with the intact animals; ** – р<0.05 in comparison with the control group. 
Table 3 
The calculation of the endothelial dysfunction coefficient in the experimental animal groups (M ± m; n = 10) 
 
Group Functional tests 
The area of the vascular 
response (relative units, RU) 
EDC 
A 
EDVD 1268.0±74.8 
1.1±0.2 
EIVD 1375.3±93.7 
B 
EDVD 814.2±78.0* 
7.2±0.6* 
EIVD 5862.3±116.7* 
C 
EDVD 1119.4±110.1** 
2.8±0.3** 
EIVD 3006.5±232.5** 
D 
EDVD 1253.3±71.5** 
2.3±0.2** 
EIVD 2823.2±114.3** 
Comment: EDVD – endothelium-dependent vasodilatation; EIVD – endothelium-independent vasodilatation; EDC – 
endothelial dysfunction coefficient; * – р<0.05 in comparison with the intact animals; ** – р<0.05 in comparison with the 
control group. 
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The results of the evaluation of the cytokine 
profile 
On the background of the modeling of 
endothelial dysfunction by the use of bacterial 
lipopolysaccharide, the concentrations of TNF-α, 
IL-6 and IL-10 increased several times and 
reached 101.88±6.87 PG/ml, 156.93±7.02 PG/ml 
and 82.78±577 PG/ml, respectively. The 
correction by tocilizumab resulted in a decrease in 
the concentration of these cytokines to the intact 
animals level at the dose of 4 mg/kg and their 
normalization at the dose of 8 mg/kg. 
 
 
Fig. 1. The influence of the test compounds on the serum concentration of tumor necrosis factor-α.  * – 
р<0.05 in comparison with the intact animals; ** – р<0.05 in comparison with the control group 
 
 
Fig. 2. The influence of the test compounds on the serum concentration of interleukin-6. * – р<0.05 in 
comparison with the intact animals; ** – р<0.05 in comparison with the control group 
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Fig. 3. The influence of the test compounds on the serum concentration of interleukin-10. * – р<0.05 in 
comparison with the intact animals; ** – р<0.05 in comparison with the control group. 
 
IL-6 is a multifunctional cytokine that is 
involved in the pathogenesis of cardiovascular 
diseases. Increased secretion of IL-6 in response 
to inflammation, increases serum concentration of 
angiotensin II, exacerbates oxidative stress and 
vascular damage that is why IL-6 has become a 
marker of vascular inflammation, i.e. the increase 
in the level of circulating interleukin 
epidemiologically associated with a number of 
clinically significant diseases of the 
cardiovascular system [16, 17].  
Increased level of circulating IL-6, leads to 
the following pathological changes, which plays 
an important role in the development of 
endothelium-associated pathology: 
• activation and maintenance of the low-
grade systemic inflammation (including a 
powerful increase in the synthesis of CRP in a 
liver); 
• disruption of homeostatic functions 
(cellular protection from reactive oxygen 
species); 
• endothelial dysfunction,  
• activation of monocytes; 
• intimal proliferation, myocardial 
hypertrophy; 
• disturbance in metabolic control (insulin 
resistance). 
These various effects indicate that IL-6 is not 
merely a passive biomarker, but actively 
modulate a course of cardiovascular diseases [18, 
19]. 
In numerous clinical studies there was proved 
the role of interleukin-6 in the pathogenesis of 
atherosclerosis [20], ischemic heart disease [16], 
hypertension [21], chronic heart failure and 
myocardial hypertrophy [16]. At the same time, 
there is confirmed and discussed not only the role 
of the increased level of IL-6 in the development 
of cardiovascular disease, but adverse effects on 
the prognosis and outcomes of the disease. 
In this regard, IL-6 began to be typified as a 
potential target for targeted therapy of such 
diseases as atherosclerosis, coronary heart 
disease, as well as with the aim of reducing 
cardiovascular risk with comorbidity. 
The most studied pleiotropic effect of 
tocilizumab is the effect on the atherosclerosis 
progression. For example, SAMURAI and 
CHARISMA studies demonstrated the increase in 
the level of HDL cholesterol in 24% of patients 
on a background of tocilizumab administration, 
and in the CHARISMA study there was observed 
a dose-dependent effect of tocilizumab: the use of 
the drug in a dose of 8 mg contributed to the 
increase in the level of HDL cholesterol and 
reduced the atherogenic index [22, 23].  
In experimental studies inhibition of IL-6 by 
tocilizumab led to improvement in endothelial 
function and reduced arterial stiffness [24].  
Preliminary data obtained in the study of a 
single dose of tocilizumab in patients with 
myocardial infarction without ST-segment 
elevation showed a tendency to decrease in the 
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areas under the curve of concentrations of CRP 
and troponin T [25]. 
In another pilot study, there was investigated 
the effect of tocilizumab on endothelial 
dysfunction and arterial wall rigidity. According 
to the results, tocilizumab significantly improved 
the endothelium-dependent vasodilation from 3.3 
± 0.8 to 4.4 ± 1.2 (after 3 months of therapy) to 
5.2 ± 1.9% (after 6 months of therapy) and 
decreased the vascular wall stiffness. Thus, the 
researchers concluded the beneficial effect of 
tocilizumab on endothelial function and the main 
pathogenetic links of cardiovascular diseases and 
complications [26].  
The high prevalence of cardiovascular 
complications in rheumatoid arthritis has led to 
the need to study the effect of targeted therapy on 
cardiovascular risk in this group of patients. So, 
52 weeks of tocilizumab therapy resulted in 
marked and significant increase in ejection 
fraction (+ 8.2%) and a significant decrease in left 
ventricular mass (-24.4%) [27].  
Data review of clinical trials published in the 
Lancet in 2012, suggests that targeting inhibition 
of the IL-6 receptors may provide a new 
therapeutic approach to the prevention and 
treatment of ischemic heart disease [28]. 
Dysfunction of endothelium, as a rule, 
involves in the pathological process not only the 
cardiovascular system but also leads to the 
development of the so-called "cardiometabolic 
continuum". Therefore, it is necessary to consider 
the potential influence of the IL-6 inhibitors on 
carbohydrate metabolism and insulin resistance. 
The first study of the influence of tocilizumab 
on carbohydrate metabolism was the study, 
during which patients with rheumatoid arthritis 
and coexisting diabetes mellitus type II was 
treated with tocilizumab at the dose of 8 mg/kg 
intravenously every 4 weeks [24]. In the subgroup 
of 10 patients, HbA1c decreased significantly 
after 1 month tocilizumab therapy (from 7.17 to 
6.35%, p <0.01), while the effect was maintained 
after 6 months (6.0%, p <0.001). 
In another study, children with systemic 
juvenile idiopathic arthritis in the presence of 
glucocorticoids dosage modification, only after 6 
weeks of tocilizumab therapy HOMA-IR index 
reflecting insulin resistance, significantly 
decreased [29]. The obtained data were confirmed 
in another cohort study (n=11): after 3 months of 
tocilizumab therapy HOMA-IR decreased 
significantly, indicating improving insulin 
sensitivity through inhibition of IL-6 signaling. 
To confirm the theory, LAR was designed as a 
new marker of insulin resistance. In keeping with 
HOMA-IR dynamics, LAR was constant during 
the first month of the study, but it was 
significantly lower than baseline after 3 months of 
therapy [30]. 
Thus, we have described the potential 
endothelium protective mechanisms of inhibition 
of signaling pathway triggered by overproduction 
of interleukin-6, which require further study, both 
in preclinical and clinical studies.  
Conclusion 
Thus, tocilizumab (at the doses of 4 mg/kg 
and 8 mg/kg) after a single dose has a pronounced 
endothelium protective activity in the model of 
endothelial dysfunction associated with the low-
grade systemic inflammation and oxidative stress 
and prevents the imbalance of the cytokine 
profile.  
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